MedTrace Logo

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

NCT05286931 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2022-03-18

No results posted yet for this study

Summary

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Conditions

  • Neisseria Gonorrhoeae Infection

Interventions

DRUG

Ciprofloxacin 500 mg

Ciprofloxacin 500 MG, taken once orally.

Sponsors & Collaborators

Principal Investigators

  • Lindley Barbee, MD, MPH · University of Washington

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286931 on ClinicalTrials.gov